10 documents found

Article / Chapter
CC BY-NC-ND 3.0
2018

Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's...

Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at...
Lausanne: Frontiers Media SA, 2018
Article / Chapter
CC BY-NC-ND 3.0
2018

Serum Inflammatory Profile for the Discrimination of Clinical Subtypes...

Background: Blood levels of immune markers have been proposed to discriminate patients with Parkinson's disease (PD) from controls. However, differences between clinical PD subgroups regarding these markers still need to be identified. Objective: To investigate whether clinical phenotypes can be predicted...
Lausanne: Frontiers Media SA, 2018
Article / Chapter
CC BY-NC-ND 3.0
2017

Corrigendum: White Matter Changes-Related Gait and Executive Function Deficits:...

[This corrects the article on p. 213 in vol. 9, PMID: 28713264.].
Lausanne: Frontiers Media SA, 2017
Article / Chapter
CC BY-NC-ND 3.0
2017

White Matter Changes-Related Gait and Executive Function Deficits: Associations...

Background: White matter changes (WMC) are a common finding among older adults and patients with Parkinson's disease (PD), and have been associated with, e.g., gait deficits and executive dysfunction. How the factors age and PD influence WMC-related deficits is, to our best knowledge, not investigated...
Lausanne: Frontiers Media SA, 2017
Article / Chapter
CC BY-NC-ND 3.0
2016

Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential...

Introduction Biomarkers indicating trait, progression and prediction of pathology and symptoms in Parkinson's disease (PD) often lack specificity or reliability. Investigating biomarker variance between individuals and over time and the effect of confounding factors is essential for the evaluation...
San Francisco: PloS one, 2016
Article / Chapter
CC BY-NC-ND 3.0
2016

Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies...

A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical onset of Parkinson’s disease (PD). Studies have identified several different prodromal markers that may have the potential to predict the conversion from healthy to clinical PD but use considerably different...
Lausanne: Frontiers Media SA, 2016
Article / Chapter
2016

Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular...

Parkinson’s disease (PD) is an example for a complex field of research, which is driven by themultifactorial etiology, the heterogeneity in phenotype and the variability in disease progression,as well as the presence of a long pre-diagnostic period, called prodromal PD, lasting up to decades(Postuma...
Lausanne: Frontiers Media SA, 2016
Article / Chapter
CC BY-NC-ND 3.0
2015

Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying...

BACKGROUND Aging processes and several vascular burden factors have been shown to increase the risk of dementia including Alzheimer's disease. While pathological alterations in dementia precede diagnosis by many years, reorganization of brain processing might temporarily delay cognitive decline. We hypothesized...
San Francisco: PloS one, 2015
Article / Chapter
CC BY-NC-ND 3.0
2014

Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease:...

Alpha-synuclein ($α$-Syn) plays a pivotal role in the pathophysiology of Parkinson's disease (PD), which can partly be modulated by innate and adaptive immune functions, and vice versa. Here, naturally occurring $α$-Syn autoantibodies ($α$-Syn-nAbs) may be effective against $α$-Syn pathoetiology and...
San Francisco: PloS one, 2014
Article / Chapter
CC BY-NC-ND 3.0
2014

A Neurodegenerative Vascular Burden Index and the Impact on Cognition

Lausanne: Frontiers Media SA, 2014